TY - JOUR
T1 - Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
AU - Chew, Serena
AU - Mackey, Melissa C.
AU - Jabbour, Elias
N1 - Publisher Copyright:
© The Author(s), 2020.
PY - 2020
Y1 - 2020
N2 - Acute myeloid leukemia (AML) is a malignancy of uncontrolled proliferation of immature myeloid blasts characterized by clonal evolution and genetic heterogeneity. FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to a third of AML cases and are associated with highly proliferative disease, shorter duration of remission, and increased rates of disease relapse. The known impact of activating mutations in FLT3 in AML on disease pathogenesis, prognosis, and response to therapy has led to the development of tyrosine kinase inhibitors targeting FLT3. Gilteritinib is a potent, second generation inhibitor of both FLT3 and AXL, designed to address the limitations of other FLT3 inhibitors, particularly in targeting mechanisms of resistance to other drugs. In this review, we present comprehensive data on recent and ongoing studies evaluating the role of gilteritinib in the relapsed and refractory FLT3 mutated AML setting.
AB - Acute myeloid leukemia (AML) is a malignancy of uncontrolled proliferation of immature myeloid blasts characterized by clonal evolution and genetic heterogeneity. FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to a third of AML cases and are associated with highly proliferative disease, shorter duration of remission, and increased rates of disease relapse. The known impact of activating mutations in FLT3 in AML on disease pathogenesis, prognosis, and response to therapy has led to the development of tyrosine kinase inhibitors targeting FLT3. Gilteritinib is a potent, second generation inhibitor of both FLT3 and AXL, designed to address the limitations of other FLT3 inhibitors, particularly in targeting mechanisms of resistance to other drugs. In this review, we present comprehensive data on recent and ongoing studies evaluating the role of gilteritinib in the relapsed and refractory FLT3 mutated AML setting.
KW - acute myeloid leukemia
KW - FLT3
KW - FMS-like tyrosine kinase 3 inhibitors
KW - gilteritinib
UR - http://www.scopus.com/inward/record.url?scp=85105301105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105301105&partnerID=8YFLogxK
U2 - 10.1177/2040620720930614
DO - 10.1177/2040620720930614
M3 - Review article
C2 - 32547718
AN - SCOPUS:85105301105
SN - 2040-6207
VL - 11
JO - Therapeutic Advances in Hematology
JF - Therapeutic Advances in Hematology
ER -